First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

This study is ongoing, but not recruiting participants.

First Received: October 1, 2007 No Changes Posted

Sponsored by:	King Faisal Specialist Hospital & Research Center
Information provided by:	King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:	NCT00537901

Purpose

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Condition	Intervention
Colonic Neoplasms Rectal Neoplasms	Radiation: First-Line Bevacizumab and Chemotherapy Drug: Bevacizumab

MedlinePlus related topics: Cancer

Drug Information available for: Bevacizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Single Group Assignment

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria: - Patients with metastatic cancer of colon or rectum

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00537901

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators

Principal Investigator:	Shouki Bazarbashi, MD	KFSH & RC
Principal Investigator:	Shouki Bazarbashi, MD	KFSH & RC

More Information

No publications provided

Study ID Numbers:	RAC #2041-082
Study First Received:	October 1, 2007
Last Updated:	October 1, 2007
ClinicalTrials.gov Identifier:	NCT00537901 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by King Faisal Specialist Hospital & Research Center:

Colon and Rectum Cancer

Study placed in the following topic categories:

Digestive System Neoplasms
Rectal Neoplasms
Gastrointestinal Diseases
Colonic Diseases
Rectal Neoplasm
Bevacizumab
Intestinal Diseases
Angiogenesis Inhibitors

Rectal Diseases
Intestinal Neoplasms
Digestive System Diseases
Rectal Cancer
Neoplasm Metastasis
Gastrointestinal Neoplasms
Colonic Neoplasms
Colorectal Neoplasms

Additional relevant MeSH terms:

Digestive System Neoplasms
Antineoplastic Agents
Rectal Neoplasms
Gastrointestinal Diseases
Growth Substances
Physiological Effects of Drugs
Colonic Diseases
Bevacizumab
Intestinal Diseases
Angiogenesis Inhibitors
Rectal Diseases

Pharmacologic Actions
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Digestive System Diseases
Therapeutic Uses
Gastrointestinal Neoplasms
Growth Inhibitors
Angiogenesis Modulating Agents
Colonic Neoplasms
Colorectal Neoplasms

ClinicalTrials.gov processed this record on May 06, 2009